Articles tagged with Cancer Cells
Researchers at the University of Bern have determined the structure of monocarboxylate transporter 4 (MCT4), a key protein in cancer cell metabolism. The study provides insights into the molecular mechanism of MCT4 and identifies promising binding sites for inhibitors, paving the way for new cancer treatments.
A new multi-organ-on-a-chip system accurately captures chemotherapies' toxic effects on liver and other organs. The technology enables flexible testing of different organ systems, potentially leading to more accurate drug development and personalized therapies.
Researchers developed a probe that accurately traces the sigma-1 receptor on ER surfaces, showing promise for studying neurological disorders and cancer. The probe was tested on prostate cancer cells, haloperidol-sensitive signal detected.
Researchers found that administering anti-inflammatory treatments before surgery can eliminate the spread of cancer cells and promote prolonged survival in animal models. These findings suggest a potential paradigm shift in cancer treatment approaches, particularly for patients undergoing resectable cancers.
A research team created an artificially produced antibody fragment that successfully blocks the transport of antibiotics and chemotherapy agents out of cancer cells. By binding to a specific protein, the fragment prevented the protein from splitting ATP, thus stopping the transport process.
Researchers at the University of Pennsylvania School of Medicine have identified a protein called TOX as the key regulator of exhausted immune cells in cancer. The discovery could lead to new immunotherapies that target or engineer TOX to reverse exhaustion and improve immunity to infections or cancer.
Researchers have identified a new type of fibroblast in pancreatic cancer tumors that can evade immune detection. The discovery, published in Cancer Discovery, highlights the complex role of these cells in protecting cancer cells and could lead to new therapeutic strategies.
Human cells use a mechanism to protect genetic transcripts from spliceosomes, preventing damage that can lead to cancer and neurodegenerative diseases. The researchers found that the snRNA of spliceosomes migrates into the cytoplasm in human cells, unlike in yeast, where it remains in the nucleus.
Researchers identified two key chemokines, CCL5 and CXCL9, as universally implicated in T cell infiltration across all solid tumors. Their simultaneous presence is a key requirement for the engraftment of T cells and establishment of 'hot tumors.'
SMU researchers develop a new approach to treat drug-resistant prostate cancer cells using a protein inhibitor and chemotherapy. The method shows promising results, increasing sensitivity of cancer cells to chemotherapeutics without harming healthy cells.
A new approach detects mutations across many different types of normal cells by analyzing RNA sequencing data from normal tissues. The study found that 95% of individuals had at least one tissue with mutations, with higher rates in lung, esophagus, and sun-exposed skin.
Ferroptotic cancer cells can stimulate the immune system, leading to activation of anticancer immunity. However, tumor cells dying by ferroptosis can also cause suppression of an antitumor immune response, contributing to cancer progression.
Researchers suggest that sexual reproduction prevents invasion of transmissible cancer by generating genetic variation and detecting foreign cells. This theory proposes a novel explanation for the evolution of sex in multicellular organisms, shifting our understanding of evolutionary biology.
Recent advances in organoid technology are revolutionizing cancer research, allowing for personalized drug testing on individual patient cells. Meanwhile, integrating organoids with organ-on-a-chip technology may overcome control challenges and enhance physiological realism, paving the way for more advanced biomedical applications.
Hollings Cancer Center researchers used a whole-organism approach to study cell division cycles, revealing two modules that work similarly in all cell types and organs. The findings confirm previous knowledge and address new questions about the regulation of E2F transcription factors.
Researchers found that regular cells can adopt immune cell characteristics, sending warning signs when stressed or in danger. This mechanism may aid in detecting cancer cells sooner, preventing tumor formation.
Researchers observed micro-perforations in the basement membrane zone, allowing inflammatory cells to access and feed growing cancer cells. This 'window' into the cancer process enables targeting of these weak spots with cancer therapeutics.
Researchers at Université de Montrêal discovered a molecular indicator for cancer progression, enabling precision medicine. They found that SRC kinases chemically modify SOCS1, leading to uncontrolled cell proliferation in cancers.
Boosting type 1 interferon production has been shown to clear viral infections and increase immunity against cancer in an animal model. Glycolysis-derived lactate plays a critical role in limiting RLR signaling, which enables the activation of type 1 IFN production.
Researchers at the University of Edinburgh have discovered a cell-wide web that transmits signals across tiny distances, allowing cells to rapidly rewire their communication networks. This discovery could lead to new insights into diseases such as pulmonary hypertension and cancer.
Researchers at NYU Abu Dhabi have developed metal-organic trefoil knots, which can deliver metals to cancer cells and induce oxidative stress. These nanoscale molecules showed high potency in vitro and in vivo against six cancer cell lines and zebrafish embryos.
A new device forces cells through tiny channels, detecting blebbing in cancer cells to identify metastatic prostate cancer. Highly metastatic cells exhibit more blebbing than normal or less-metastatic cells.
Researchers discovered E. coli bacteria change behavior to navigate tiny obstacle courses, defying predictions of slowing progress. The study's findings have implications for biology, medicine, and robotic search-and-rescue tactics.
Researchers at Medical University of South Carolina identified a metabolic Achilles heel in cancer, exploiting glutamine addiction. A new combination treatment has shown promise in treating drug-resistant esophageal cancer cells.
Researchers at Dartmouth College and City University of Hong Kong developed a swimming robot with a light-controlled cellular engine that can perform highly-targeted drug delivery. The biohybrid device transforms its shape when exposed to skin-penetrating near-infrared light, allowing it to drive and brake through fluid environments.
A Yale study reveals how cediranib, a cancer drug of limited use, stops certain cancer cells from repairing their DNA to survive. The combination of cediranib with olaparib may deliver a lethal blow in cancers that rely on a specific DNA repair pathway.
Researchers found that targeting telomeres with oxidative stress can shorten them, leading to accelerated cellular aging and DNA instability. This could lead to potential cancer treatment strategies by stopping cancer cells from dividing.
Researchers developed cell membrane-coated nanocarriers to overcome immune clearance and biotoxicity issues. These biomimetic hybrids achieve improved biocompatibility, circulation time, and therapeutic efficiency.
A study published in ACS Central Science found that many DNA cage nanostructures are not taken up by cells, but rather degraded by enzymes outside the cell. The researchers' findings have significant implications for the use of DNA strands as a tool for delivering therapeutic agents into diseased cells.
Researchers at MD Anderson Cancer Center discovered a small molecule drug, IACS-10759, that targets metabolic reprogramming and inhibits OXPHOS, leading to marked growth inhibition in ibrutinib-resistant mantle cell lymphoma cells. The study provides hope for patients with this incurable B-cell lymphoma.
Researchers discovered that fibrinogen, a blood-clotting protein, plays a role in multiple sclerosis relapses. In a mouse model, injecting EVs containing fibrinogen activated CD8+ immune cells, leading to relapsing-remitting disease.
Researchers at Swansea University's Medical School have found that immune cells can re-programme their metabolic pathways to provide energy and building blocks when challenged. This discovery suggests that manipulating metabolism could lead to new therapies for infectious diseases and cancer.
Researchers have identified a key enzyme that helps cancer cells survive by eliminating junk RNA. Targeting this enzyme, ADAR, may lead to breakthroughs in treating various types of cancer.
Cells lacking CD13 protein can't move normally, hindering their ability to repair wounds and metastasize. Researchers discovered that CD13 acts as an organizer, gathering recycled integrin proteins at the cell membrane to enable movement.
Researchers found that cancer cells can capitalize on temporary gaps in endothelial cell layers caused by physical forces and mechanical stresses, allowing them to migrate through and colonize new organs. This opportunistic approach complements chemical signaling and enables cancer cells to spread more efficiently.
A study at UT MD Anderson Cancer Center identified a new therapeutic target in cancer cells, caseinolytic protease P (ClpP), which breaks down proteins within mitochondria. New anti-cancer agents called imipridones activate ClpP and cause cancer cell death via mitochondrial proteolysis.
Researchers have developed a computational approach to simulate the complex bioelectrical interaction at the tissue scale, enabling more accurate and capable virtual experiments of cell behavior. The technique has potential applications in treating cancer and accelerating combat wound healing.
Researchers found that MDM2 interacts with a mitochondrial protein to promote cancer cell death. Nutlin-3A enhances this interaction, helping kill cancer cells.
Researchers found that removing the ATDC gene from pancreatic cells prevented the development of pancreatic cancer in mice. The study identified ATDC as a key player in the reprogramming of adult cells into primitive, high-growth cell types, which can lead to cancer.
Researchers created SCOTfluors, a class of small fluorophores that can be attached to common metabolites and emit light in the visible to near-infrared range. This allows for the observation of metabolite trafficking in living cells without destroying them.
Researchers have engineered molecules that restrict access to heme, an oxygen-binding molecule, to slow the growth of lung cancer tumors in mice. By starving cancer cells of this essential molecule, the new approach may provide a potential new path forward in treating non-small cell lung cancer.
Researchers find a long-overlooked molecular machine in the cell nucleus, the spliceosome, that produces mutant gene/protein fueling cancerous cells. Targeting this protein with existing and developing drugs may offer new treatment options for aggressive leukemia.
Researchers have shed light on how leukemia cells become resistant to drugs and describe a potential solution using two drugs in combination. The study identifies the genes responsible for resistance, revealing that cancer cells overcome the lack of asparagine by breaking down proteins.
Researchers found that the nutrient composition of interstitial fluid surrounding pancreatic tumors differs from blood and culture medium used to grow cancer cells. This discrepancy suggests growing cancer cells in a more similar environment could help predict how experimental drugs will affect cancer cells.
A new diagnostic method for pancreatic cancer has been developed by researchers at the University of Copenhagen, utilizing circular DNA to identify cancer cells in blood tests. The technology is expected to classify cancer cells in individual patients and implement personalized treatment regimens, leading to increased survival rates.
Cancer cells dependent on WRN enzyme to survive due to DNA repair system loss; MSI signature identified as effective biomarker for vulnerable tumors.
Scientists developed a new imaging technology to visualize what cells eat, such as glucose, which could aid in the diagnosis and treatment of diseases like cancer. The technique uses chemical probes that light up when they attach to specific molecules consumed by cells.
Researchers found that Chop expression is higher in T cells from ovarian cancer patients, and high nuclear levels of Chop are associated with poor clinical responses. Blocking Chop or ER stress may help improve T cell-based immunotherapy treatments.
A new study reveals blocking specific regions of UHRF1 switches on hundreds of cancer-fighting genes, impairing colorectal cancer cells' ability to grow and spread. This protein is akin to a molecular Swiss army knife, with many different parts that each have a different job.
Researchers found that leukocytes select the path of least resistance by using their nucleus to measure pore sizes and guide movement. The nucleus acts as a mechanical gauge, pushing forward to insert into multiple pores to determine the largest size.
The study reveals the full structure of human ACLY at high resolution, paving the way for targeted drug development. ACLY inhibition could provide a better approach for treating cancer and metabolic disorders.
Researchers have developed a computational model for human MEK1, a protein with potential as a drug target for various human cancers. The model provides insights into the structure and function of MEK1, which can help develop new classes of inhibitors for cancer therapeutics.
Researchers found that combining adavosertib with irinotecan, navitoclax or capecitabine increased its effectiveness against pancreatic cancer. The study aimed to identify new combinations of drugs to enhance adavosertib's effect.
Researchers have unraveled the inner workings of a process that allows T cells to tune out fake signals, providing an enormous leap forward in understanding immune system fine-tuning. The discovery sheds light on why immune system activity sometimes goes awry and may provide insights into curing cancer.
Researchers use laser technology to improve on existing methods for measuring metabolic activity in cancer cells. The new technique, single-cell metabolic photoacoustic microscopy, allows for the analysis of around 3,000 cells in about 15 minutes, enabling more accurate assessments of cancer cell characteristics.
Researchers discovered that a cellular protein acts as a 'gas pump attendant' controlling cancer cell growth, ensuring only necessary proteins are produced. This understanding may lead to new ways to inhibit cancer development.
Researchers identified a critical protein for tumor cell survival and found that targeting it could be a novel treatment strategy for MSI-H tumors. The study suggests that pharmacological inhibition of WRN function might serve as a targeted therapeutic approach.
Researchers identified two proteins, SIX1 and SIX2, that act as gatekeepers to regulate the immune response. The proteins were found to be involved in reducing inflammation by dampening the noncanonical NF-κB pathway.
Researchers discovered that adult tissues maintain a catalog of genes active in embryonic development, which can be accessed under certain conditions. This finding has major implications for regenerative medicine, as cells from patients may be coaxed into an earlier stage of development to replace diseased or failing organs.
Researchers found that cancer cells with fewer mitochondria are more likely to respond to certain drug treatments, offering a new avenue for targeted therapies. The study's findings suggest that enhancing understanding of the relationship between mitochondrial variability and drug response may lead to more effective cancer treatments.